Compare RVPH & ESTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | ESTA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Costa Rica |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 2.1B |
| IPO Year | N/A | 2018 |
| Metric | RVPH | ESTA |
|---|---|---|
| Price | $0.30 | $65.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $3.14 | ★ $78.86 |
| AVG Volume (30 Days) | ★ 5.6M | 413.3K |
| Earning Date | 11-13-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,973,000.00 |
| Revenue This Year | N/A | $29.17 |
| Revenue Next Year | N/A | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.76 |
| 52 Week Low | $0.25 | $26.56 |
| 52 Week High | $2.15 | $78.24 |
| Indicator | RVPH | ESTA |
|---|---|---|
| Relative Strength Index (RSI) | 34.99 | 43.12 |
| Support Level | $0.32 | $63.29 |
| Resistance Level | $0.37 | $69.59 |
| Average True Range (ATR) | 0.03 | 3.67 |
| MACD | 0.01 | -0.47 |
| Stochastic Oscillator | 8.34 | 15.76 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.